Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Diluted Average) (2021 - 2026)

Centessa Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 5 years, most recently at $135.7 million for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 18.56% to $135.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $135.7 million through Dec 2025, up 18.56% year-over-year, with the annual reading at $135.7 million for FY2025, 18.56% up from the prior year.
  • Shares Outstanding (Diluted Average) was $135.7 million for Q4 2025 at Centessa Pharmaceuticals, up from $133.6 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $135.7 million in Q4 2025 and troughed at $75.2 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Diluted Average) is $96.2 million (2023), against an average of $105.3 million.
  • Year-over-year, Shares Outstanding (Diluted Average) grew 1.34% in 2023 and then skyrocketed 33.18% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $75.2 million in 2021, then grew by 24.26% to $93.4 million in 2022, then rose by 2.97% to $96.2 million in 2023, then increased by 19.02% to $114.5 million in 2024, then grew by 18.56% to $135.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Shares Outstanding (Diluted Average) are $135.7 million (Q4 2025), $133.6 million (Q3 2025), and $133.4 million (Q2 2025).